Edwards Lifesciences Corp (NYSE:EW) CEO Michael A. Mussallem sold 49,100 shares of the company’s stock in a transaction dated Wednesday, May 3rd. The stock was sold at an average price of $109.71, for a total value of $5,386,761.00. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.
Michael A. Mussallem also recently made the following trade(s):
- On Friday, April 28th, Michael A. Mussallem sold 49,100 shares of Edwards Lifesciences Corp stock. The stock was sold at an average price of $109.78, for a total value of $5,390,198.00.
- On Thursday, February 16th, Michael A. Mussallem sold 49,100 shares of Edwards Lifesciences Corp stock. The stock was sold at an average price of $89.63, for a total value of $4,400,833.00.
Shares of Edwards Lifesciences Corp (NYSE:EW) traded up 0.84% during trading on Friday, hitting $112.89. The stock had a trading volume of 253,658 shares. The firm has a 50-day moving average of $102.70 and a 200 day moving average of $94.65. Edwards Lifesciences Corp has a 1-year low of $81.12 and a 1-year high of $121.75. The company has a market capitalization of $23.68 billion, a P/E ratio of 37.53 and a beta of 0.53.
Edwards Lifesciences Corp (NYSE:EW) last posted its quarterly earnings data on Tuesday, April 25th. The medical research company reported $0.94 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.82 by $0.12. The firm had revenue of $883.50 million for the quarter, compared to analysts’ expectations of $776.51 million. Edwards Lifesciences Corp had a net margin of 19.22% and a return on equity of 25.00%. The business’s quarterly revenue was up 26.7% on a year-over-year basis. During the same quarter last year, the company posted $0.71 EPS. Equities research analysts predict that Edwards Lifesciences Corp will post $3.53 earnings per share for the current fiscal year.
COPYRIGHT VIOLATION WARNING: “Insider Selling: Edwards Lifesciences Corp (EW) CEO Sells 49,100 Shares of Stock” was posted by Sports Perspectives and is owned by of Sports Perspectives. If you are viewing this report on another site, it was illegally copied and republished in violation of United States and international copyright & trademark legislation. The correct version of this report can be read at https://sportsperspectives.com/2017/05/19/michael-a-mussallem-sells-49100-shares-of-edwards-lifesciences-corp-ew-stock-updated.html.
Several equities analysts recently weighed in on the company. Zacks Investment Research cut Edwards Lifesciences Corp from a “buy” rating to a “hold” rating in a research report on Thursday. Goldman Sachs Group Inc assumed coverage on Edwards Lifesciences Corp in a research report on Tuesday. They set a “conviction-buy” rating and a $138.00 price objective for the company. Vetr cut Edwards Lifesciences Corp from a “strong-buy” rating to a “buy” rating and set a $124.67 price objective for the company. in a research report on Monday. Jefferies Group LLC reissued a “buy” rating on shares of Edwards Lifesciences Corp in a research report on Wednesday, April 26th. Finally, Royal Bank of Canada boosted their price objective on Edwards Lifesciences Corp from $116.00 to $120.00 and gave the stock an “outperform” rating in a research report on Wednesday, April 26th. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating, seventeen have issued a buy rating and one has assigned a strong buy rating to the company. The company presently has an average rating of “Buy” and an average target price of $119.77.
Large investors have recently made changes to their positions in the stock. Quadrant Capital Group LLC raised its stake in shares of Edwards Lifesciences Corp by 3.5% in the first quarter. Quadrant Capital Group LLC now owns 1,209 shares of the medical research company’s stock worth $109,000 after buying an additional 41 shares during the last quarter. YorkBridge Wealth Partners LLC acquired a new stake in Edwards Lifesciences Corp during the first quarter valued at approximately $110,000. NEXT Financial Group Inc raised its stake in Edwards Lifesciences Corp by 91.7% in the first quarter. NEXT Financial Group Inc now owns 1,045 shares of the medical research company’s stock valued at $115,000 after buying an additional 500 shares during the last quarter. TCI Wealth Advisors Inc. boosted its position in shares of Edwards Lifesciences Corp by 30.5% in the third quarter. TCI Wealth Advisors Inc. now owns 1,044 shares of the medical research company’s stock valued at $126,000 after buying an additional 244 shares during the period. Finally, Advantage Investment Management LLC purchased a new position in shares of Edwards Lifesciences Corp during the fourth quarter valued at about $145,000. 83.99% of the stock is currently owned by hedge funds and other institutional investors.
Edwards Lifesciences Corp Company Profile
Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.
Receive News & Ratings for Edwards Lifesciences Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences Corp and related companies with MarketBeat.com's FREE daily email newsletter.